Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized CRISPR
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized…
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences Professional…
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration…
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing Professional…
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative…
Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS platform
Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD…
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary…